Sign in
Taking peopleNo phase

How urine copper changes over the day in Wilson disease

Studies daily urine copper patterns in people with Wilson disease.

Key facts

Who runs it
Hospices Civils de Lyon
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Circadian Variation of Urinary Copper Excretion in Wilson Disease Patients
Status
Recruiting
People taking part
30 people, planned
Started
10 Jan 2025
Expected to end
10 Feb 2027
Type of study
Observational, 3 groups
Treatments tested
  • urine and blood test
Record updated
15 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with Wilson disease who take D-Pencillamine, Trientine or Zinc. It studies which time of day urine copper levels most closely reflect a full 24-hour urine collection.

Age
6 years to 70 years
Sex
All sexes
Disease stage
Confirmed Wilson disease (Leipzig score ˃4).
Earlier treatment
Must currently take D-Pencillamine, Trientine or Zinc. No change in treatment within the last 6 months.

Main reasons for not taking part

  • Change in treatment within the last 6 months
  • Past liver transplant
  • Known long-term kidney failure (GFR < 30 ml/min)
  • Long-term use of diuretics (water pills) or corticosteroids
  • Not able to collect urine over 24 hours

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Patients with a confirmed diagnosis of Wilson's Disease (Leipzig score ˃4)
  • Age ≥ 6 years and ≤70 years
  • Patient able to perform 24h urine
  • Current treatment with D-Pencillamine, Trientine or Zinc
  • Non-opposition of patient and/or legal representatives for minor patients

Who cannot take part

  • Patients who had a change in treatment within the last 6 months before the inclusion
  • Patients who have undergone liver transplantation
  • Patients on long-term diuretic or corticosteroid therapy
  • Patients with known chronic renal failure (GFR < 30 ml/min)
  • Persons deprived of liberty by a judicial or administrative decision
  • Patient under judicial protection, unable to express consent

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 6 and 70 years old?

This trial is currently available in France.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Wilson's disease (WD) is a genetic disorder characterized by an accumulation of copper in the body, mainly in the liver and brain. Patients suffering from this disease are monitored by liver function tests, blood copper levels, and 24-hour urinary copper determinations.

Read full original descriptionShow less

Treatment is based either on chelating the copper accumulated in the body using D-penicillamine or Trientine or on limiting intestinal copper absorption with zinc salts.

Monitoring copper elimination in urine collected over 24 hours is essential for estimating a patient's copper load, adapting treatment dosage, and detecting any copper deficiency.

Nevertheless, urine collection is often complicated for patients, given the obvious constraints of collecting urine over 24 hours. Without this, clinical decisions are usually made based on spot urine.

There is no official recommendation for monitoring urinary copper elimination other than on 24-hour urine.

According to studies on healthy volunteers under physiological conditions, urinary copper elimination occurs according to a circadian rhythm, with minimal copper elimination between 8 pm and 4 am and maximum between 8 am and noon.

The study would aim to find the period of the day best correlated with 24h urinary copper excretion

The 3 groups in the trial

  • Group 1 - DP

    Patients with a confirmed diagnosis of Wilson's Disease (Leipzig score ˃4 ). Aged between 6 years and 70 years. Treated with D-Pencillamine

    Treatment: urine and blood test

  • Group 2 - Trientine

    Patients with a confirmed diagnosis of Wilson's Disease (Leipzig score ˃4 ). Aged between 6 years and 70 years. Treated with Trientine

    Treatment: urine and blood test

  • Group 3 - ZINC

    Patients with a confirmed diagnosis of Wilson's Disease (Leipzig score ˃4 ). Aged between 6 years and 70 years. Treated with Zinc.

    Treatment: urine and blood test

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Circadian Variation of Urinary Copper Excretion in Wilson Disease Patients Treated With Chelators or Zinc Salts
Plain-language title
How urine copper changes over the day in Wilson diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT06430359, who can take part
Record updated
15 January 2026